Adia Med ($ADIA) is working towards a future where national standards govern the use of stem cell therapies. These standards aim to eliminate variability in treatment quality and establish a system of accountability and transparency.

With a focus on third-party verification, donor screening, and strict quality control measures, Adia Med is ensuring that stem cell treatments are both effective and safe for patients. The company’s efforts are expected to improve patient outcomes, restore confidence in the industry, and help push regenerative medicine toward mainstream acceptance.

By aligning with federal regulatory agencies like the FDA and DHHS, Adia Med hopes to ensure that stem cell therapies are subject to the same rigorous oversight as other medical treatments, leading to a stronger, more reliable industry overall.

Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks

$ADIA #StemCellTherapy

$ADIA ~ Adia Med’s Vision for the Future of Stem Cell Therapy

Adia Med ($ADIA) is working towards a future where national standards govern the use of stem cell therapies. These standards aim to eliminate variability in treatment quality and establish a system of accountability and transparency.

With a focus on third-party verification, donor screening, and strict quality control measures, Adia Med is ensuring that stem cell treatments are both effective and safe for patients. The company’s efforts are expected to improve patient outcomes, restore confidence in the industry, and help push regenerative medicine toward mainstream acceptance.

By aligning with federal regulatory agencies like the FDA and DHHS, Adia Med hopes to ensure that stem cell therapies are subject to the same rigorous oversight as other medical treatments, leading to a stronger, more reliable industry overall.

Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks

$ADIA ~ Adia Med’s Vision for the Future of Stem Cell Therapy

Adia Med ($ADIA) is working towards a future where national standards govern the use of stem cell therapies. These standards aim to eliminate variability in treatment quality and establish a system of accountability and transparency.

With a focus on third-party verification, donor screening, and strict quality control measures, Adia Med is ensuring that stem cell treatments are both effective and safe for patients. The company’s efforts are expected to improve patient outcomes, restore confidence in the industry, and help push regenerative medicine toward mainstream acceptance.

By aligning with federal regulatory agencies like the FDA and DHHS, Adia Med hopes to ensure that stem cell therapies are subject to the same rigorous oversight as other medical treatments, leading to a stronger, more reliable industry overall.

Adia Med Pushes for National Stem Cell Standards, OTCQB Uplist
https://allcapresearch.com/penny-stocks/f/adia-med-pushes-for-national-stem-cell-standards-otcqb-uplist?blogcategory=Pennystocks

$ADIA news out! Adia Med is creating a national certification system to verify the quantity & viability of stem cells in every treatment. Patients will soon receive third-party certified documentation, guaranteeing they’re getting exactly what they need.

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

$ADIA news out! Adia Med is creating a national certification system to verify the quantity & viability of stem cells in every treatment. Patients will soon receive third-party certified documentation, guaranteeing they’re getting exactly what they need.

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

Nice update. Stem cell therapy has the potential to revolutionize medicine—but only if it’s safe, standardized, and reliable. Adia Med’s new protocols will set homologous use standards, quality controls, and third-party verification to ensure every patient gets the best treatment possible.

Adia Med Leads Charge to Standardize Umbilical Cord Stem Cell Use Nationwide, Prepares Presentation for New Head of DHHS and FDA
https://www.newsfilecorp.com/release/243473/Adia-Med-Leads-Charge-to-Standardize-Umbilical-Cord-Stem-Cell-Use-Nationwide-Prepares-Presentation-for-New-Head-of-DHHS-and-FDA

Some interesting buying coming now. All buys today, so far:

Plus the company is working with a PCAOB-registered accounting firm to complete a third-party audit—the first step in its plan to uplist to OTCQB and eventually Nasdaq Small Cap!

Here’s why this matters:

✅ OTCQB uplisting = More credibility & transparency 📊
✅ Increased liquidity = More trading volume, stronger price action 💰
✅ Bigger investor base = Institutional money on the horizon 💵
✅ Roadmap to Nasdaq Small Cap is in place 🚀

$ADIA ~ The company is working with a PCAOB-registered accounting firm to complete a third-party audit—the first step in its plan to uplist to OTCQB and eventually Nasdaq Small Cap!

Here’s why this matters:

✅ OTCQB uplisting = More credibility & transparency 📊
✅ Increased liquidity = More trading volume, stronger price action 💰
✅ Bigger investor base = Institutional money on the horizon 💵
✅ Roadmap to Nasdaq Small Cap is in place 🚀

$ADIA has already been making waves in stem cell therapy with its FDA-compliant U.S.-based clinic, and now the company is solidifying its market position with a legit financial audit & uplisting efforts. This is a huge step toward serious long-term growth—watch closely!

$ADIA ~ The company is working with a PCAOB-registered accounting firm to complete a third-party audit—the first step in its plan to uplist to OTCQB and eventually Nasdaq Small Cap!

Here’s why this matters:

✅ OTCQB uplisting = More credibility & transparency 📊
✅ Increased liquidity = More trading volume, stronger price action 💰
✅ Bigger investor base = Institutional money on the horizon 💵
✅ Roadmap to Nasdaq Small Cap is in place 🚀

$ADIA has already been making waves in stem cell therapy with its FDA-compliant U.S.-based clinic, and now the company is solidifying its market position with a legit financial audit & uplisting efforts. This is a huge step toward serious long-term growth—watch closely!

ADIA Nutrition is actively expanding its footprint with Adia Med and Adia Labs. The company is hiring skilled sales reps to promote groundbreaking stem cell therapies, including Adia Vita, a private-label umbilical cord stem cell product. With a clear roadmap for growth, this is a fantastic time to be a part of ADIA’s future in the regenerative medicine industry. #StemCellTherapy #RegenerativeMedicine #Expansion #Healthcare

Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion
https://www.newsfilecorp.com/release/243941/Adia-Nutrition-Hunts-for-Top-Sales-Talent-to-Power-Adia-Med-and-Adia-Labs-Expansion

ADIA Nutrition is actively expanding its footprint with Adia Med and Adia Labs. The company is hiring skilled sales reps to promote groundbreaking stem cell therapies, including Adia Vita, a private-label umbilical cord stem cell product. With a clear roadmap for growth, this is a fantastic time to be a part of ADIA’s future in the regenerative medicine industry. #StemCellTherapy #RegenerativeMedicine #Expansion #Healthcare

Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion
https://www.newsfilecorp.com/release/243941/Adia-Nutrition-Hunts-for-Top-Sales-Talent-to-Power-Adia-Med-and-Adia-Labs-Expansion

ADIA Continues to Scale Up! >>

Adia Nutrition Hunts for Top Sales Talent to Power Adia Med and Adia Labs Expansion
https://www.newsfilecorp.com/release/243941/Adia-Nutrition-Hunts-for-Top-Sales-Talent-to-Power-Adia-Med-and-Adia-Labs-Expansion

Adia has undergone a major transformation—shifting from nutritional supplements to stem cell research & regenerative medicine. The company recently launched its first clinic and is already planning expansions.

📊 Technical indicators suggest upside:
✔ Trading above all key SMAs (8, 20, 50, 200-day)
✔ MACD & accumulation trends pointing bullish
✔ RSI at 58.71—showing strength without overbought conditions
✔ Resistance at $0.09 tested multiple times, with upside potential to $0.12–$0.15

With growing institutional interest in stem cell therapy, will $ADIA retest its 52-week high of $0.1720? Keep it on your watchlist! 🚀 #Biotech #StemCell #ADIA

Adia Nutrition ($ADIA) has undergone a major transformation—shifting from nutritional supplements to stem cell research & regenerative medicine. The company recently launched its first clinic and is already planning expansions.
📊 Technical indicators suggest upside:
✔ Trading above all key SMAs (8, 20, 50, 200-day)
✔ MACD & accumulation trends pointing bullish
✔ RSI at 58.71—showing strength without overbought conditions
✔ Resistance at $0.09 tested multiple times, with upside potential to $0.12–$0.15
With growing institutional interest in stem cell therapy, will $ADIA retest its 52-week high of $0.1720? Keep it on your watchlist! 🚀 #Biotech #StemCell #ADIA

Adia Nutrition ($ADIA) has undergone a major transformation—shifting from nutritional supplements to stem cell research & regenerative medicine. The company recently launched its first clinic and is already planning expansions.
📊 Technical indicators suggest upside:
✔ Trading above all key SMAs (8, 20, 50, 200-day)
✔ MACD & accumulation trends pointing bullish
✔ RSI at 58.71—showing strength without overbought conditions
✔ Resistance at $0.09 tested multiple times, with upside potential to $0.12–$0.15
With growing institutional interest in stem cell therapy, will $ADIA retest its 52-week high of $0.1720? Keep it on your watchlist! 🚀 #Biotech #StemCell #ADIA

Nice update out. Additionally, ADIA Nutrition’s CEO, Larry Powalisz, has promoted his longtime intern to aide, offloading key projects, marketing, and social media. This change allows leadership to focus on strategic expansion while maintaining our mission-driven approach.

$ADIA ~ With the stem cell industry projected to grow significantly in the coming years, Adia Nutrition ($ADIA) is positioning itself as an emerging player. The company recently opened its first stem cell treatment clinic and has hinted at expanding locations + partnerships with medical institutions.

📊 Technical Strength:
✔ Trading above key moving averages
✔ RSI at 58.71, signaling strong momentum
✔ MACD remains bullish 📈
✔ Accumulation trending up, buyers stepping in

Three Stocks to Watch for a Spring Breakout: CBDW, ADIA, and RDGL
https://allcapresearch.com/f/three-stocks-to-watch-for-a-spring-breakout-cbdw-adia-and-rdgl

$ADIA ~ With the stem cell industry projected to grow significantly in the coming years, Adia Nutrition ($ADIA) is positioning itself as an emerging player. The company recently opened its first stem cell treatment clinic and has hinted at expanding locations + partnerships with medical institutions.

📊 Technical Strength:
✔ Trading above key moving averages
✔ RSI at 58.71, signaling strong momentum
✔ MACD remains bullish 📈
✔ Accumulation trending up, buyers stepping in

Three Stocks to Watch for a Spring Breakout: CBDW, ADIA, and RDGL
https://allcapresearch.com/f/three-stocks-to-watch-for-a-spring-breakout-cbdw-adia-and-rdgl

Agreed. Once volume steps back in it will be an easy push past .10 and higher.

✔ Trading above all key SMAs (8, 20, 50, 200-day)
✔ MACD & accumulation trends pointing bullish
✔ RSI at 58.71—showing strength without overbought conditions
✔ Resistance at $0.09 tested multiple times, with massive upside potential

Check out the huge bids setting up at .07. Very nice!
$ADIA

.09 up this morning. I have some bids set just in case, but if volume hits ADIA will go over .10 quickly.

$ADIA ~ Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings
✅ Secures brand protection and trust.
✅ Introduces cutting-edge stem cell therapy.
✅ Sets a new industry standard.

$ADIA ~ Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings
✅ Secures brand protection and trust.
✅ Introduces cutting-edge stem cell therapy.
✅ Sets a new industry standard.

Yesterday's patent news was an awesome update for ADIA. Expecting to see .10 break this week.

Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings
✅ Secures brand protection and trust.
✅ Introduces cutting-edge stem cell therapy.
✅ Sets a new industry standard.

Nice bids going into close, stacked at .08.
$ADIA

Fat bid sitting at .065.

Nice! Trademark filings strengthen ADIA's brand identity.

Patent news out! $ADIA

In a bold move to solidify its position in the competitive field of regenerative medicine, ADIA Nutrition Inc. (OTC Pink: ADIA) has filed for trademarks on its newest product, "Adia Vita," and its powerful new slogan, "The Platinum Standard in Stem Cell Therapy." These trademark applications, currently pending approval by the U.S. Patent and Trademark Office (USPTO), aim to protect ADIA’s innovation and ensure that its stem cell therapies remain synonymous with excellence. As the stem cell market grows rapidly, ADIA Nutrition stands out with its commitment to authenticity and superior offerings. The company’s CEO, Larry Powalisz, emphasized that these trademarks are about more than just legal protection—they represent ADIA’s promise to deliver the real deal to customers and healthcare providers alike. With Adia Vita and "The Platinum Standard," ADIA is setting the stage for the future of stem cell therapy.

Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings

$ADIA Nutrition Takes Major Step in Brand Protection with Trademark Filings
In a bold move to solidify its position in the competitive field of regenerative medicine, ADIA Nutrition Inc. (OTC Pink: ADIA) has filed for trademarks on its newest product, "Adia Vita," and its powerful new slogan, "The Platinum Standard in Stem Cell Therapy." These trademark applications, currently pending approval by the U.S. Patent and Trademark Office (USPTO), aim to protect ADIA’s innovation and ensure that its stem cell therapies remain synonymous with excellence. As the stem cell market grows rapidly, ADIA Nutrition stands out with its commitment to authenticity and superior offerings. The company’s CEO, Larry Powalisz, emphasized that these trademarks are about more than just legal protection—they represent ADIA’s promise to deliver the real deal to customers and healthcare providers alike. With Adia Vita and "The Platinum Standard," ADIA is setting the stage for the future of stem cell therapy.

Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings

$ADIA Nutrition Takes Major Step in Brand Protection with Trademark Filings
In a bold move to solidify its position in the competitive field of regenerative medicine, ADIA Nutrition Inc. (OTC Pink: ADIA) has filed for trademarks on its newest product, "Adia Vita," and its powerful new slogan, "The Platinum Standard in Stem Cell Therapy." These trademark applications, currently pending approval by the U.S. Patent and Trademark Office (USPTO), aim to protect ADIA’s innovation and ensure that its stem cell therapies remain synonymous with excellence. As the stem cell market grows rapidly, ADIA Nutrition stands out with its commitment to authenticity and superior offerings. The company’s CEO, Larry Powalisz, emphasized that these trademarks are about more than just legal protection—they represent ADIA’s promise to deliver the real deal to customers and healthcare providers alike. With Adia Vita and "The Platinum Standard," ADIA is setting the stage for the future of stem cell therapy.

Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
https://www.newsfilecorp.com/release/243145/Adia-Nutrition-Moves-to-Secure-Brand-Identity-with-Trademark-Filings

Feature in Nasdaq today!
The global stem cell therapy market is entering an era of unprecedented growth and innovation. Valued at $5.13 billion in 2024, the U.S. stem cell market alone is projected to reach $15.79 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.9%. Globally, the market is expected to hit $28.89 billion by 2030, fueled by advancements in regenerative medicine, increased government funding for research, and the development of groundbreaking therapies for conditions like cancer, autoimmune diseases, and genetic disorders.

Nasdaq: The Future of Stem Cell Investing: Spotlight on Smaller Innovators #StemCellTherapy
https://www.nasdaq.com/press-release/future-stem-cell-investing-spotlight-smaller-innovators-2025-03-04

$ADIA featured in Nasdaq: The Future of Stem Cell Investing: Spotlight on Smaller Innovators #StemCellTherapy
https://www.nasdaq.com/press-release/future-stem-cell-investing-spotlight-smaller-innovators-2025-03-04

$ADIA featured in Nasdaq: The Future of Stem Cell Investing: Spotlight on Smaller Innovators #StemCellTherapy
https://www.nasdaq.com/press-release/future-stem-cell-investing-spotlight-smaller-innovators-2025-03-04

Agreed! No dilution. Nice to see in an OTC stock, with plans to uplist. Article out covering this:

ADIA Nutrition (OTC: ADIA) Expands, Eyes OTCQB Uplisting
https://allcapresearch.com/f/adia-nutrition-otc-adia-expands-eyes-otcqb-uplisting

$ADIA keep on strong watch! Lots of big updates hit last week taking ADIA from low .01s to a high of .17! Currently consolidating in the 07 range, with more updates on the horizon. Here is a recap. Keep in mind ADIA is a low float stock.

✅ Feb 3: Adia Med enters the $15.1B global stem cell market with FDA-compliant treatments! 💉🌍 #RegenerativeMedicine

✅ Feb 5: ADIA appoints a PCAOB-registered audit firm—OTCQB uplisting in progress! 📈 #OTCQB

✅ Feb 11: 25M shares retired, reducing dilution & strengthening shareholder value! 🔥 #ShareReduction

✅ Feb 13: Florida AHCA registration advances, moving toward insurance coverage for stem cell therapy! 🏥 #HealthcareRevolution

✅ Feb 18: ADIA partners with an FDA-approved lab—100M stem cells & 3T exosomes per dose! 🧬 #Biotech

✅ Feb 20: Adia Labs launches Adia Vita, a branded stem cell product for clinical & research use! 🚀 #StemCellScience

✅ Feb 24: Nationwide Med Spa expansion confirmed—bringing stem cell therapy to high-demand regions! 🏙️ #HealthWellness

✅ Feb 26: Shell risk designation removed, a major step toward OTCQB uplisting! ✅ #InvestorConfidence

✅ Feb 28: February ends with breakthroughs in regenerative medicine & corporate milestones—ADIA is on fire! 🔥🚀 #GrowthStock

$ADIA keep on strong watch! Lots of big updates hit last week taking ADIA from low .01s to a high of .17! Currently consolidating in the 07 range, with more updates on the horizon. Here is a recap. Keep in mind ADIA is a low float stock.

✅ Feb 3: Adia Med enters the $15.1B global stem cell market with FDA-compliant treatments! 💉🌍 #RegenerativeMedicine

✅ Feb 5: ADIA appoints a PCAOB-registered audit firm—OTCQB uplisting in progress! 📈 #OTCQB

✅ Feb 11: 25M shares retired, reducing dilution & strengthening shareholder value! 🔥 #ShareReduction

✅ Feb 13: Florida AHCA registration advances, moving toward insurance coverage for stem cell therapy! 🏥 #HealthcareRevolution

✅ Feb 18: ADIA partners with an FDA-approved lab—100M stem cells & 3T exosomes per dose! 🧬 #Biotech

✅ Feb 20: Adia Labs launches Adia Vita, a branded stem cell product for clinical & research use! 🚀 #StemCellScience

✅ Feb 24: Nationwide Med Spa expansion confirmed—bringing stem cell therapy to high-demand regions! 🏙️ #HealthWellness

✅ Feb 26: Shell risk designation removed, a major step toward OTCQB uplisting! ✅ #InvestorConfidence

✅ Feb 28: February ends with breakthroughs in regenerative medicine & corporate milestones—ADIA is on fire! 🔥🚀 #GrowthStock

Complete recap of last months news/updates for $ADIA

✅ Feb 3: Adia Med enters the $15.1B global stem cell market with FDA-compliant treatments! 💉🌍 #RegenerativeMedicine

✅ Feb 5: ADIA appoints a PCAOB-registered audit firm—OTCQB uplisting in progress! 📈 #OTCQB

✅ Feb 11: 25M shares retired, reducing dilution & strengthening shareholder value! 🔥 #ShareReduction

✅ Feb 13: Florida AHCA registration advances, moving toward insurance coverage for stem cell therapy! 🏥 #HealthcareRevolution

✅ Feb 18: ADIA partners with an FDA-approved lab—100M stem cells & 3T exosomes per dose! 🧬 #Biotech

✅ Feb 20: Adia Labs launches Adia Vita, a branded stem cell product for clinical & research use! 🚀 #StemCellScience

✅ Feb 24: Nationwide Med Spa expansion confirmed—bringing stem cell therapy to high-demand regions! 🏙️ #HealthWellness

✅ Feb 26: Shell risk designation removed, a major step toward OTCQB uplisting! ✅ #InvestorConfidence

✅ Feb 28: February ends with breakthroughs in regenerative medicine & corporate milestones—ADIA is on fire! 🔥🚀 #GrowthStock

$ADIA news out! >> ADIA Nutrition Inc. Ignites 2025 with February Breakthroughs, Riding Adia Med's Profitable January Triumph
https://finance.yahoo.com/news/adia-nutrition-inc-ignites-2025-153000400.html

Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhancing investor visibility, and delivering cutting-edge solutions nationwide.

February's transformative journey began on February 3, when Adia Med, the medical division of ADIA Nutrition, officially entered the $15.1 billion global stem cell market. Offering FDA-compliant treatments using 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps), the clinic leverages high-quality umbilical cord stem cells to address conditions like inflammation, autoimmune disorders, and orthopedic issues-providing a U.S.-based alternative to international hubs like Panama and Switzerland. On February 5, the company took a significant step toward uplisting from OTC Pink to the OTCQB Venture Market by appointing a PCAOB-registered accounting firm for a third-party audit, boosting transparency and laying groundwork for a future Nasdaq Small Cap listing.

The month gained further traction mid-February. On February 11, ADIA Nutrition tackled historical share issuance concerns, pledging to retire over 25 million undocumented shares-cutting outstanding shares by approximately 15 percent-and reinforcing its commitment to shareholder integrity. On February 13, Adia Med advanced its registration with Florida's Agency for Health Care Administration (AHCA), aiming to secure private insurance coverage for therapies like Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and stem cell injectables, enhancing affordability. On February 18, a partnership with a premier FDA-approved laboratory ensured a steady supply of top-tier umbilical cord stem cell and exosome products, featuring 100 million viable cells and 3 trillion exosomes per dose, cementing Adia Med's leadership in regenerative medicine quality.

February's pinnacle arrived with three standout milestones that underscored ADIA Nutrition's rapid progress in regenerative medicine and corporate growth. These achievements highlighted the company's innovation, scalability, and commitment to enhancing investor confidence, marking a transformative close to the month.

February's Standout Milestones:

- February 20: ADIA Nutrition launched Adia Labs LLC, unveiling Adia Vita-a branded stem cell product containing 100 million viable cells and 3 trillion exosomes per dose for clinical research and therapeutic use, targeting a market of over 1 million doctors and clinics.

- February 24: Adia Med announced a nationwide expansion plan, partnering with elite Medical Spas to create satellite locations in health-conscious regions, offering a scalable, low-risk model to boost revenue and service reach.

- February 26: ADIA Nutrition achieved a critical corporate victory as OTC Markets removed its shell risk designation, a key requirement for OTCQB uplisting, expedited through close collaboration with OTC Markets, highlighting the company's operational integrity and accelerating its path to greater liquidity and investor trust.

These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue. Treating conditions like Multiple Sclerosis (MS), hip issues, torn tendons, and joint pain with umbilical cord stem cells (UCB-SC), the clinic demonstrated the wide-reaching impact of its regenerative therapies. "January's financial strength gave us a solid base, and February's leaps-including the shell risk removal and Adia Labs' progress-propel us forward," said Larry Powalisz, CEO of ADIA Nutrition. "We're thrilled to thank OTC Markets for their swift support in clearing this hurdle, allowing me to share exciting updates with our investors that I couldn't before. This is just the start."

The OTCQB uplisting process, now in clear sight with the shell risk designation lifted, will elevate ADIA Nutrition's visibility to a broader investor audience. The Med Spa partnerships will efficiently scale operations, while the lab collaboration ensures product excellence. The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.

Looking forward, ADIA Nutrition plans to replicate the Winter Park Clinic model in new markets, expand satellite locations, and complete its OTCQB uplisting with Nasdaq aspirations on the horizon. These efforts promise enhanced shareholder value and cutting-edge care for diverse communities. "From January's financial win to February's strategic breakthroughs, we're redefining healthcare possibilities," Powalisz added. "We're committed to innovation, accessibility, and sustainable growth for our stakeholders."

For questions, inquiries, or further information, contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
ADIA Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, it operates two key divisions: a supplement division offering premium, organic supplements, and a medical division establishing clinics specializing in leading-edge stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these efforts, ADIA Nutrition empowers individuals to live their best lives by addressing nutritional needs and groundbreaking medical treatments.

$ADIA news out! >> ADIA Nutrition Inc. Ignites 2025 with February Breakthroughs, Riding Adia Med's Profitable January Triumph
https://finance.yahoo.com/news/adia-nutrition-inc-ignites-2025-153000400.html

Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhancing investor visibility, and delivering cutting-edge solutions nationwide.

February's transformative journey began on February 3, when Adia Med, the medical division of ADIA Nutrition, officially entered the $15.1 billion global stem cell market. Offering FDA-compliant treatments using 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps), the clinic leverages high-quality umbilical cord stem cells to address conditions like inflammation, autoimmune disorders, and orthopedic issues-providing a U.S.-based alternative to international hubs like Panama and Switzerland. On February 5, the company took a significant step toward uplisting from OTC Pink to the OTCQB Venture Market by appointing a PCAOB-registered accounting firm for a third-party audit, boosting transparency and laying groundwork for a future Nasdaq Small Cap listing.

The month gained further traction mid-February. On February 11, ADIA Nutrition tackled historical share issuance concerns, pledging to retire over 25 million undocumented shares-cutting outstanding shares by approximately 15 percent-and reinforcing its commitment to shareholder integrity. On February 13, Adia Med advanced its registration with Florida's Agency for Health Care Administration (AHCA), aiming to secure private insurance coverage for therapies like Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and stem cell injectables, enhancing affordability. On February 18, a partnership with a premier FDA-approved laboratory ensured a steady supply of top-tier umbilical cord stem cell and exosome products, featuring 100 million viable cells and 3 trillion exosomes per dose, cementing Adia Med's leadership in regenerative medicine quality.

February's pinnacle arrived with three standout milestones that underscored ADIA Nutrition's rapid progress in regenerative medicine and corporate growth. These achievements highlighted the company's innovation, scalability, and commitment to enhancing investor confidence, marking a transformative close to the month.

February's Standout Milestones:

- February 20: ADIA Nutrition launched Adia Labs LLC, unveiling Adia Vita-a branded stem cell product containing 100 million viable cells and 3 trillion exosomes per dose for clinical research and therapeutic use, targeting a market of over 1 million doctors and clinics.

- February 24: Adia Med announced a nationwide expansion plan, partnering with elite Medical Spas to create satellite locations in health-conscious regions, offering a scalable, low-risk model to boost revenue and service reach.

- February 26: ADIA Nutrition achieved a critical corporate victory as OTC Markets removed its shell risk designation, a key requirement for OTCQB uplisting, expedited through close collaboration with OTC Markets, highlighting the company's operational integrity and accelerating its path to greater liquidity and investor trust.

These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue. Treating conditions like Multiple Sclerosis (MS), hip issues, torn tendons, and joint pain with umbilical cord stem cells (UCB-SC), the clinic demonstrated the wide-reaching impact of its regenerative therapies. "January's financial strength gave us a solid base, and February's leaps-including the shell risk removal and Adia Labs' progress-propel us forward," said Larry Powalisz, CEO of ADIA Nutrition. "We're thrilled to thank OTC Markets for their swift support in clearing this hurdle, allowing me to share exciting updates with our investors that I couldn't before. This is just the start."

The OTCQB uplisting process, now in clear sight with the shell risk designation lifted, will elevate ADIA Nutrition's visibility to a broader investor audience. The Med Spa partnerships will efficiently scale operations, while the lab collaboration ensures product excellence. The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.

Looking forward, ADIA Nutrition plans to replicate the Winter Park Clinic model in new markets, expand satellite locations, and complete its OTCQB uplisting with Nasdaq aspirations on the horizon. These efforts promise enhanced shareholder value and cutting-edge care for diverse communities. "From January's financial win to February's strategic breakthroughs, we're redefining healthcare possibilities," Powalisz added. "We're committed to innovation, accessibility, and sustainable growth for our stakeholders."

For questions, inquiries, or further information, contact Larry Powalisz at ceo @101Dahlias-0850.

About ADIA Nutrition Inc.:
ADIA Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, it operates two key divisions: a supplement division offering premium, organic supplements, and a medical division establishing clinics specializing in leading-edge stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these efforts, ADIA Nutrition empowers individuals to live their best lives by addressing nutritional needs and groundbreaking medical treatments.